Literature DB >> 11446135

The practice of discounting in economic evaluations of healthcare interventions.

D H Smith1, H Gravelle.   

Abstract

OBJECTIVES: Discounting of costs in health-related economic evaluation is generally regarded as uncontroversial, but there is disagreement about discounting health benefits. We sought to explore the current recommendations and practice in health economic evaluations with regard to discounting of costs and benefits.
METHODS: Recommendations for best practice on discounting for health effects as set out by government agencies, regulatory bodies, learned journals, and leading health economics texts were surveyed. A review of a sample of primary literature on health economic evaluations was undertaken to ascertain the actual current practice on discounting health effects and costs.
RESULTS: All of the official sources recommended a positive discount rate for both health effects and costs, and most recommended a specific rate (range, 1% to 8%). The most frequently specified rates were 3% and 5%. A total of 147 studies were reviewed; most of these used a discount rate for health of either 0% (n = 50) or 5% (n = 67). Over 90% of studies used the same discount rate for both health and cost. While 28% used a zero rate for both health and cost, in 64% a nonzero rate was used for both. Studies where the health measure was in natural clinical units (direct) were significantly more likely to have a zero discount rate.
CONCLUSION: The finding that 28% of studies did not discount costs or benefits is surprising and concerning. A lower likelihood of discounting for benefits when they are in natural units may indicate confusion regarding the rationale for discounting health effects.

Mesh:

Year:  2001        PMID: 11446135     DOI: 10.1017/s0266462300105094

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  36 in total

1.  Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration.

Authors:  Martin E Backhouse
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 2.  Theoretical arguments for the discounting of health consequences: where do we go from here?

Authors:  Angelina Lazaro
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 3.  Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases.

Authors:  Jasper M Bos; Philippe Beutels; Lieven Annemans; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Discounting health effects in pharmacoeconomic evaluations: current controversies.

Authors:  J M Bos; Maarten J Postma; Lieven Annemans
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Cost-effectiveness of new tests to diagnose and treat coronary heart disease.

Authors:  Leslee J Shaw; Allen J Taylor; Patrick G O'Malley
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-08

6.  Need for differential discounting of costs and health effects in cost effectiveness analyses.

Authors:  Werner B F Brouwer; Louis W Niessen; Maarten J Postma; Frans F H Rutten
Journal:  BMJ       Date:  2005-08-20

7.  Societal discounting of health effects in cost-effectiveness analyses: the influence of life expectancy.

Authors:  Suzanne Polinder; Willem Jan Meerding; Job van Exel; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  Conceptual framework for standard economic evaluation of physical activity programs in primary prevention.

Authors:  Silke B Wolfenstetter
Journal:  Prev Sci       Date:  2011-12

9.  Healthcare costs and obesity prevention: drug costs and other sector-specific consequences.

Authors:  David R Rappange; Werner B F Brouwer; Rudolf T Hoogenveen; Pieter H M Van Baal
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 10.  Economic evaluation and transferability of physical activity programmes in primary prevention: a systematic review.

Authors:  Silke B Wolfenstetter; Christina M Wenig
Journal:  Int J Environ Res Public Health       Date:  2010-04-09       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.